Advertisement

Role of Aspirin in Breast Cancer Survival

  • Wendy Y. ChenEmail author
  • Michelle D. Holmes
Breast Cancer (B Overmoyer, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Breast Cancer

Abstract

Chemotherapy and hormonal therapy have significantly decreased breast cancer mortality, although with considerable side effects and financial costs. In the USA, over three million women are living after a breast cancer diagnosis and are eager for new treatments that are low in toxicity and cost. Multiple observational studies have reported improved breast cancer survival with regular aspirin use. Furthermore, pooled data from five large randomized trials of aspirin for cardiovascular disease showed that subjects on aspirin had decreased risk of cancer mortality and decreased risk of metastatic cancer. Although the potential mechanism for aspirin preventing breast cancer is not known, possible pathways may involve platelets, inflammation, cyclooxygenase (COX) 2, hormones, or PI3 kinase. This review article summarizes the current epidemiologic and clinical trial evidence as well as possible underlying mechanisms that justify current phase III randomized trials of aspirin to improve breast cancer survival.

Keywords

Breast cancer Aspirin Survival Inflammation COX-2 

Notes

Compliance With Ethical Standards

Conflict of Interest

Wendy Y. Chen and Michelle D. Holmes have received aspirin and placebo from Bayer Pharmaceuticals for a randomized trial of aspirin for breast cancer survivors. Dr. Chen serves as the study chair, and Dr. Holmes serves as the co-principal investigator.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Elwood PC, et al. Aspirin in the treatment of cancer: reductions in metastatic spread and in mortality: a systematic review and meta-analyses of published studies. PLoS One. 2016;11(4):e0152402.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    • Huang XZ, et al. Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis. Cancer Causes Control. 2015;26(4):589–600. This meta-analysis evaluates the association both including and excluding the randomized trial aspirin data CrossRefPubMedGoogle Scholar
  3. 3.
    Zhong S, et al. Association between aspirin use and mortality in breast cancer patients: a meta-analysis of observational studies. Breast Cancer Res Treat. 2015;150(1):199–207.CrossRefPubMedGoogle Scholar
  4. 4.
    Blair CK, et al. NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat. 2007;101(2):191–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Fraser, D.M., et al., Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. Br J Cancer. 2014;111(3):623–7.Google Scholar
  6. 6.
    Holmes, M.D., et al., Aspirin intake and survival after breast cancer. J Clin Oncol. 2010;28(9):1467–72.Google Scholar
  7. 7.
    Holmes MD, et al. Aspirin intake and breast cancer survival—a nation-wide study using prospectively recorded data in Sweden. BMC Cancer. 2014;14:391.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Murray LJ, et al. Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice Research Datalink. Breast Cancer Res. 2014;16(2):R34.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Wernli KJ, et al. Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. Pharmacoepidemiol Drug Saf. 2011;20(2):131–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Barron TI, et al. Recent prediagnostic aspirin use, lymph node involvement, and 5-year mortality in women with stage I-III breast cancer: a nationwide population-based cohort study. Cancer Res. 2014;74(15):4065–77.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Rothwell PM, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379(9826):1591–601.CrossRefPubMedGoogle Scholar
  12. 12.
    Falandry C, et al. Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. Breast Cancer Res Treat. 2009;116(3):501–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Dirix LY, et al. Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib. J Clin Oncol. 2008;26(8):1253–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Dang CT, et al. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res. 2004;10(12 Pt 1):4062–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Martin LA, et al. Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer. Breast Cancer Res Treat. 2010;123(3):829–36.CrossRefPubMedGoogle Scholar
  16. 16.
    Brandao RD, et al. A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. Breast cancer research : BCR. 2013;15(2):R29.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Aristarco V, et al. A randomized, placebo-controlled, phase II, presurgical biomarker trial of celecoxib versus exemestane in postmenopausal breast cancer patients. Cancer Prev Res (Phila). 2016;9(5):349–56.CrossRefGoogle Scholar
  18. 18.
    Chow LW, et al. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol. 2008;111(1–2):13–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Goss PE, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27—a randomized controlled phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(11):1398–404.CrossRefGoogle Scholar
  20. 20.
    Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999;18(55):7908–16.CrossRefPubMedGoogle Scholar
  21. 21.
    Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer. 2006;6(2):130–40.CrossRefPubMedGoogle Scholar
  22. 22.
    Bennett A, et al. Prostaglandins and breast cancer. Lancet. 1977;2(8039):624–6.CrossRefPubMedGoogle Scholar
  23. 23.
    McFadden DW, et al. Additive effects of Cox-1 and Cox-2 inhibition on breast cancer in vitro. Int J Oncol. 2006;29(4):1019–23.PubMedGoogle Scholar
  24. 24.
    Liu W, et al. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth. Am J Clin Oncol. 2003;26(4):S103–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83(3):493–501.CrossRefPubMedGoogle Scholar
  26. 26.
    Ristimaki A, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002;62(3):632–5.PubMedGoogle Scholar
  27. 27.
    Denkert C, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer. 2003;97(12):2978–87.CrossRefPubMedGoogle Scholar
  28. 28.
    Wulfing P, et al. Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol. 2003;129(7):375–82.CrossRefPubMedGoogle Scholar
  29. 29.
    Baylin A, et al. Adipose tissue biomarkers of fatty acid intake. Am J Clin Nutr. 2002;76(4):750–7.PubMedGoogle Scholar
  30. 30.
    Costa C, et al. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol. 2002;55(6):429–34.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Subbaramaiah K, et al. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem. 2002;277(21):18649–57.CrossRefPubMedGoogle Scholar
  32. 32.
    Ranger GS, et al. Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Res. 2004;24(4):2349–51.PubMedGoogle Scholar
  33. 33.
    Spizzo G, et al. Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer. 2003;88(4):574–8.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Holmes MD, et al. COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat. 2011;130(2):657–62.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    • Hugo HJ, et al. New insights on COX-2 in chronic inflammation driving breast cancer growth and metastasis. J Mammary Gland Biol Neoplasia. 2015;20(3–4):109–19. This article reviews potential mechanisms linking COX-2, inflammation, aspirin, and breast cancer CrossRefPubMedGoogle Scholar
  36. 36.
    Zelenay S, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015;162(6):1257–70.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Liu XH, Rose DP. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res. 1996;56(22):5125–7.PubMedGoogle Scholar
  38. 38.
    Natarajan K, et al. Exposure of human breast cancer cells to the anti-inflammatory agent indomethacin alters choline phospholipid metabolites and Nm23 expression. Neoplasia. 2002;4(5):409–16.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Hwang D, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 1998;90(6):455–60.CrossRefPubMedGoogle Scholar
  40. 40.
    Yoshimura N, et al. Expression of cyclooxygenase-1 and -2 in human breast cancer. Surg Today. 2003;33(11):805–11.CrossRefPubMedGoogle Scholar
  41. 41.
    Basu S, et al. Cellular expression of cyclooxygenase, aromatase, adipokines, inflammation and cell proliferation markers in breast cancer specimen. PLoS One. 2015;10(10):e0138443.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11(2):123–34.CrossRefPubMedGoogle Scholar
  43. 43.
    Sierko E, Wojtukiewicz MZ. Inhibition of platelet function: does it offer a chance of better cancer progression control? Semin Thromb Hemost. 2007;33(7):712–21.CrossRefPubMedGoogle Scholar
  44. 44.
    Mohle R, et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A. 1997;94(2):663–8.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Coppinger JA, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood. 2004;103(6):2096–104.CrossRefPubMedGoogle Scholar
  46. 46.
    Smyth SS, et al. Platelet functions beyond hemostasis. J Thromb Haemost. 2009;7(11):1759–66.CrossRefPubMedGoogle Scholar
  47. 47.
    Holmes CE, et al. Initiation of aspirin therapy modulates angiogenic protein levels in women with breast cancer receiving tamoxifen therapy. Clin Transl Sci. 2013;6(5):386–90.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Sindelar WF, Tralka TS, Ketcham AS. Electron microscopic observations on formation of pulmonary metastases. J Surg Res. 1975;18(2):137–61.CrossRefPubMedGoogle Scholar
  49. 49.
    Borsig L, et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A. 2001;98(6):3352–7.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Nieswandt B, et al. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999;59(6):1295–300.PubMedGoogle Scholar
  51. 51.
    Felding-Habermann B, et al. Role of beta3 integrins in melanoma cell adhesion to activated platelets under flow. J Biol Chem. 1996;271(10):5892–900.CrossRefPubMedGoogle Scholar
  52. 52.
    Elwood PC, et al. Aspirin, salicylates, and cancer. Lancet. 2009;373(9671):1301–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Rocca B, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A. 2002;99(11):7634–9.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Pulcinelli FM, et al. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol. 2004;43(6):979–84.CrossRefPubMedGoogle Scholar
  55. 55.
    Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550–62.CrossRefPubMedGoogle Scholar
  56. 56.
    Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129(7):1261–74.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Franke TF, et al. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science. 1997;275(5300):665–8.CrossRefPubMedGoogle Scholar
  58. 58.
    Banerji S, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012;486(7403):405–9.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Dasari A, Messersmith WA. New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. Clin Cancer Res. 2010;16(15):3811–8.CrossRefPubMedGoogle Scholar
  60. 60.
    Pandolfi PP. Breast cancer—loss of PTEN predicts resistance to treatment. N Engl J Med. 2004;351(22):2337–8.CrossRefPubMedGoogle Scholar
  61. 61.
    Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7(8):606–19.CrossRefPubMedGoogle Scholar
  62. 62.
    Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene. 2008;27(41):5486–96.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.CrossRefGoogle Scholar
  64. 64.
    Glynn SA, et al. COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer. BMC Cancer. 2010;10:626.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Liao X, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367(17):1596–606.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    • Domingo E, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol. 2013;31(34):4297–305. This is one of several studies that show that the aspirin association for colorectal cancer is more strongly seen with PI3K mutant tumors CrossRefPubMedGoogle Scholar
  67. 67.
    Din FV, et al. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology. 2012;142(7):1504–15. e3 CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Hudson AG, et al. Nonsteroidal anti-inflammatory drug use and serum total estradiol in postmenopausal women. Cancer Epidemiol Biomark Prev. 2008;17(3):680–7.CrossRefGoogle Scholar
  69. 69.
    Carey LA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–502.CrossRefPubMedGoogle Scholar
  70. 70.
    Duggan, C., et al., Aspirin and serum estrogens in postmenopausal women: a randomized controlled clinical trial. Cancer Prev Res. 2014;7(9):906–912.Google Scholar
  71. 71.
    Fortner RT, et al. Analgesic use and patterns of estrogen metabolism in premenopausal women. Horm Cancer. 2014;5(2):104–12.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Burstein HJ, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014;32(21):2255–69.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Brodie AM, et al. Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol. 2001;79(1–5):41–7.CrossRefPubMedGoogle Scholar
  74. 74.
    Brueggemeier RW, et al. Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. J Steroid Biochem Mol Biol. 2005;95(1–5):129–36.CrossRefPubMedGoogle Scholar
  75. 75.
    Karuppu D, et al. Aromatase and prostaglandin inter-relationships in breast adipose tissue: significance for breast cancer development. Breast Cancer Res Treat. 2002;76(2):103–9.CrossRefPubMedGoogle Scholar
  76. 76.
    Subbaramaiah K, et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov. 2012;2(4):356–65.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    • Bowers LW, et al. NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions. Cancer Res. 2014;74(16):4446–57. This study combines both epidemiologic and in vitro data to evaluate how NSAID use may decrease breast cancer recurrence CrossRefPubMedGoogle Scholar
  78. 78.
    Morris PG, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res. 2011;4(7):1021–9.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of Medical OncologyDana Farber Cancer InstituteBostonUSA
  2. 2.Channing Division of Network MedicineBrigham and Women’s HospitalBostonUSA
  3. 3.Department of EpidemiologyHarvard T.H. Chan School of Public HealthBostonUSA

Personalised recommendations